- New research collaborations with Max Delbrück Centre for Molecular Medicine and Helmholtz Zentrum München entered
- Public funding by German Federal Ministry of Education and Research within "m4 Cluster Initiative" increased
Martinsried/Munich, 22 September, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces that its subsidiary Trianta Immunotherapies GmbH entered two new research collaborations for further development of its immunotherapy platform TABs (T-cell-specific AntiBodies) for the treatment of various types of cancer and autoimmune diseases. In the future, scientists of the Max Delbrück Center for Molecular Medicine (MDC) and the Helmholtz Zentrum München - German Research Center for Environmental Health, Munich (HMGU) will undertake single research and development tasks in this special field.
Preclinical in vivo data about the treatment of autoimmune diseases and T cell leukemia with monoclonal antibodies generated during the granted period will be of great value for further clinical development of this immunotherapy platform. Overall, the collaboration with both research institutions offers Medigene extended scientific synergies regarding technology transfer, infrastructure and exchange of knowledge.
Additionally, Trianta will receive increased public funding for its immunotherapy platform TABs. The grant which has already been awarded by the Federal Ministry of Education and Research, (Bundesministerium für Bildung und Forschung = BMBF) within the scope of the "m4 - Personalized Medicine and Targeted Therapies: a new Dimension of Drug Development" Munich Leading-Edge Cluster initiative in beginning of June, now has been increased. The sponsored project intends to provide evidence of the elimination of pathogenic T cells in T-cell leukemia and autoimmune diseases, applying in-vivo and in-vitro methods with T-cell receptor-specific monoclonal antibodies. The project is financed by Medigene (60%) as well as the BMBF grant (40%).
About the leading-edge cluster "m4 - Personalised Medicine and Targeted Therapies":
The project is funded by the program 'm4 - Personalised Medicine and Targeted Therapies' for which the Munich Biotech Cluster was awarded 'Leading-Edge cluster status' by the German Federal Ministry of Research and Education (BMBF) in 2010. For a 5 year period, the program is funded with EUR 40 million from the BMBF, which are complemented by EUR 40 million from the participating companies in more than 50 cooperative R&D projects from industry and scientific institutions. The Bavarian Ministry of Economic Affairs and Media, Energy and Technology supports the cluster management agency BioM and in particular the m4 pre-seed concept with an additional EUR 12 million. For more information please visit www.m4.de.
About Anti-TCR monoclonal antibodies (TABs): The TABs immunotherapy platform serves to generate monoclonal antibodies which recognise different T cells based on their T cell receptors (TABs = T cell-specific antibodies). These TABs are intended to remove unwanted cells from the body in order to treat T cell-induced diseases such as T cell leukaemia or various autoimmune diseases. Monoclonal antibodies which are able to distinguish between different T cell receptors have already been produced and characterised. Proof of technology was established in preclinical experiments.
About Trianta: Based on more than 15 years of extensive research in the field of immunotherapy, Trianta Immunotherapies GmbH was founded late 2013 as a spin-off of the Helmholtz Zentrum München and was acquired by Medigene as a 100% subsidiary in January 2014. Trianta pursues three complementary immunotherapeutic strategies to target various tumour types and stages: next generation antigen-tailored dendritic cell (DC) vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please visit: www.medigene.de/unsubscribe